Drugs for Gastrointestinal Diseases Practice Questions

Q: Which of the following drugs is NOT indicated in drug-induced vomiting?

Hyoscine. **Explanation:** The management of vomiting depends on the specific receptors involved in the triggering pathway. Drug-induced vomiting (caused by chemotherapy, opioids, or general anesthetics) primarily triggers the **Chemoreceptor Trigger Zone (CTZ)** located in the area postrema. The CTZ is rich in **Dopamine (D2)**, **Serotonin (5-HT3)**, and **Neurokinin (NK1)** receptors. **Why Hyoscine is the Correct Answer:** Hyoscine (Scopolamine) is an anticholinergic drug that acts on **M1 receptors** in the vestibular apparatus and the vomiting center. It is the drug of choice for **motion sickness**, but it has no significant effect on the CTZ. Therefore, it is ineffective and **not indicated** for drug-induced or metabolic causes of vomiting. **Analysis of Incorrect Options:** * **Metoclopramide:** A D2 receptor antagonist that acts centrally on the CTZ and peripherally as a prokinetic. It is commonly used for drug-induced emesis (except cisplatin-induced). * **Ondansetron:** A potent 5-HT3 receptor antagonist. It is the gold standard for preventing chemotherapy-induced and post-operative nausea and vomiting (PONV). * **Chlorpromazine:** A broad-spectrum antiemetic (neuroleptics group) that blocks D2 receptors in the CTZ. It is effective against most drug-induced and systemic causes of vomiting. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of choice for Motion Sickness:** Hyoscine (transdermal patch is most effective). * **Drug of choice for Morning Sickness:** Doxylamine + Pyridoxine. * **Drug of choice for Cisplatin-induced vomiting:** Ondansetron (often combined with Dexamethasone or Aprepitant). * **Vomiting Center vs. CTZ:** The CTZ is outside the blood-brain barrier (BBB), making it easily accessible to circulating drugs and toxins.

Q: Which of the following is useful to decrease mortality and renal failure in acute liver disease due to alcoholism?

Pentoxifylline. **Explanation:** **Pentoxifylline** is the correct answer because it is a non-selective phosphodiesterase inhibitor that reduces the production of **Tumor Necrosis Factor-alpha (TNF-α)**. In severe alcoholic hepatitis, TNF-α is a key mediator of systemic inflammation and hepatocyte injury. Clinical trials have demonstrated that Pentoxifylline significantly reduces the risk of **hepatorenal syndrome (HRS)**, thereby decreasing mortality in patients with severe acute alcoholic hepatitis, especially when corticosteroids are contraindicated. **Analysis of Incorrect Options:** * **Orlistat:** A gastric and pancreatic lipase inhibitor used for weight loss. It prevents the absorption of dietary fats and has no role in acute liver failure or mortality reduction in alcoholic hepatitis. * **S-Adenosyl methionine (SAMe):** A precursor to glutathione. While it has been studied for chronic liver disease to improve antioxidant status, it has not shown a definitive mortality benefit in acute alcoholic liver disease. * **Syrlamysin (Silymarin):** An extract from milk thistle used as a "hepatoprotective" agent. While it has antioxidant properties, it lacks robust clinical evidence for reducing mortality or preventing renal failure in acute alcoholic hepatitis. **High-Yield Clinical Pearls for NEET-PG:** * **Maddrey Discriminant Function (MDF):** A score >32 indicates severe alcoholic hepatitis where treatment is required. * **First-line Treatment:** Prednisolone is generally the first-line treatment for severe alcoholic hepatitis. * **Pentoxifylline Indication:** Used as an alternative to steroids or when steroids are contraindicated (e.g., active infection, GI bleed) specifically to prevent renal failure. * **Mechanism:** Pentoxifylline improves microcirculation by increasing erythrocyte flexibility and decreasing blood viscosity.

Q: Which of the following drugs inhibits the release of acetylcholine from cholinergic nerves in the submucosa and myenteric complex?

Loperamide. **Explanation:** **Loperamide** is a synthetic opioid agonist that acts primarily on the **$\mu$-opioid receptors** located in the myenteric plexus of the intestinal wall. When these receptors are activated, they inhibit the release of **acetylcholine** and prostaglandins. Since acetylcholine is the primary excitatory neurotransmitter responsible for intestinal propulsive motility, its inhibition leads to decreased peristalsis and increased intestinal transit time. This allows for greater water absorption, making it an effective anti-diarrheal agent. Unlike morphine, loperamide does not cross the blood-brain barrier in therapeutic doses, thus lacking central analgesic effects. **Analysis of Incorrect Options:** * **Pectin (A):** This is a dietary fiber (bulk-forming agent) that works by absorbing water and adding bulk to the stool. It does not interfere with neurotransmitter release. * **Docusate (B):** This is a stool softener (anionic surfactant). it works by lowering the surface tension of the stool, allowing water and lipids to penetrate the fecal mass. * **Cholestyramine (D):** This is a bile acid sequestrant. It is used to treat diarrhea specifically caused by bile acid malabsorption (e.g., post-ileal resection) by binding bile salts in the lumen. **NEET-PG High-Yield Pearls:** * **Mechanism:** Loperamide = $\mu$-receptor agonist $\rightarrow$ $\downarrow$ Acetylcholine $\rightarrow$ $\downarrow$ Motility. * **Contraindication:** Avoid in infectious diarrhea (e.g., *Shigella*, *Salmonella*) as slowing motility can delay the clearance of toxins and lead to **Toxic Megacolon**. * **Comparison:** Unlike Diphenoxylate (another opioid anti-diarrheal), Loperamide has negligible abuse potential and does not require co-administration with Atropine.

Q: Which drug is implicated for prolonging the QT interval in a premature baby?

Cisapride. **Explanation:** **Cisapride** is a prokinetic agent that acts as a serotonin (5-HT4) receptor agonist. It was historically used for gastroesophageal reflux disease (GERD) in infants. However, it is notorious for causing **QT interval prolongation** and life-threatening ventricular arrhythmias like **Torsades de Pointes**. This occurs because Cisapride blocks the **hERG (human Ether-à-go-go-Related Gene) potassium channels** in the heart, delaying ventricular repolarization. Premature babies are at higher risk due to immature hepatic metabolism (CYP3A4), leading to toxic drug accumulation. **Analysis of Incorrect Options:** * **Domperidone (A):** While it can also prolong the QT interval (especially at high doses or IV), it is generally considered safer than Cisapride and is not the "classic" drug implicated in pediatric QT prolongation in exam scenarios. * **Metoclopramide (B):** This D2-receptor antagonist is associated with extrapyramidal side effects (dystonias) in children, rather than cardiac arrhythmias. * **Omeprazole (D):** A Proton Pump Inhibitor (PPI) that is generally safe regarding cardiac conduction; its primary concerns in neonates are increased risk of infections (NEC or pneumonia). **High-Yield Clinical Pearls for NEET-PG:** * **Drug Interaction:** Cisapride toxicity is significantly increased when co-administered with **CYP3A4 inhibitors** (e.g., Erythromycin, Ketoconazole). * **Regulatory Status:** Due to the risk of sudden cardiac death, Cisapride has been withdrawn or highly restricted in most global markets. * **Other QT-prolonging drugs:** Macrolides, Fluoroquinolones, Antipsychotics (Haloperidol), and Class IA/III Anti-arrhythmics.

Q: What makes the combination of magnesium and aluminum hydroxide superior as an antacid?

All of the above.. The combination of **Magnesium hydroxide** and **Aluminum hydroxide** is a classic pharmacological strategy designed to maximize efficacy while neutralizing individual side effects. ### **Why Option D is Correct:** 1. **Rapid and Sustained Action:** Magnesium hydroxide is highly soluble and reacts quickly with HCl, providing **rapid relief**. Aluminum hydroxide dissolves slowly, providing a **sustained** neutralizing effect. Together, they cover the entire therapeutic window. 2. **Gastric Emptying:** Individual antacids can affect gastric motility; however, the combination has a negligible effect on the rate of gastric emptying compared to single-agent formulations. 3. **Bowel Movement Neutralization:** This is the most high-yield concept. Magnesium salts are osmotic laxatives (causing **diarrhea**), while Aluminum salts are smooth muscle relaxants and astringents (causing **constipation**). When combined, their effects on the bowel cancel each other out, maintaining normal motility. ### **Analysis of Options:** * **Options A, B, and C** are all physiologically accurate benefits of the combination. Since all three contribute to the clinical superiority of the mixture, "All of the above" is the most comprehensive choice. ### **NEET-PG High-Yield Pearls:** * **Systemic vs. Non-systemic:** Both are non-systemic antacids (they do not cause metabolic alkalosis, unlike Sodium Bicarbonate). * **Drug Interactions:** Antacids can chelate other drugs. Remember the mnemonic **"ANTACID"**: Avoid taking with **A**zithromycin/Antibiotics (Tetracyclines/Fluoroquinolones), **N**itrofurantoin, **T**hyroxine, and **I**ron, as they decrease their absorption. * **Renal Failure:** Avoid Magnesium-containing antacids in patients with renal failure to prevent hypermagnesemia (can lead to cardiac arrhythmias and neuromuscular blockade).

Q: Which one of the drugs is useful in treating Crohn's disease?

Infliximab. **Explanation:** **Infliximab** is the correct answer because it is a chimeric monoclonal antibody that binds to and neutralizes **Tumor Necrosis Factor-alpha (TNF-α)**, a key pro-inflammatory cytokine in the pathogenesis of Crohn’s disease. It is specifically indicated for inducing and maintaining remission in moderate-to-severe Crohn's disease, especially in patients who are unresponsive to conventional therapy or those with **fistulizing disease**. **Analysis of Incorrect Options:** * **Azathioprine (Option B):** While used as a steroid-sparing maintenance agent in Crohn’s, it is a prodrug of 6-mercaptopurine. It has a slow onset of action (3–6 months) and is generally not used for acute induction or as a primary "curative" biological intervention in the same category as TNF inhibitors. * **Tacrolimus (Option C):** This calcineurin inhibitor is occasionally used for refractory ulcerative colitis or perianal Crohn’s, but it is not a first-line or standard systemic treatment for Crohn’s disease compared to Infliximab. * **Cyclosporine (Option D):** It is highly effective for **acute severe Ulcerative Colitis** (rescue therapy to avoid colectomy) but has shown **minimal to no benefit** in treating Crohn’s disease. **NEET-PG High-Yield Pearls:** * **TNF-α Inhibitors:** Infliximab (chimeric), Adalimumab (fully human), and Certolizumab (pegylated) are all used in Crohn’s. * **Pre-treatment Screening:** Always screen for **Latent Tuberculosis** (via PPD/IGRA) and Hepatitis B before starting Infliximab, as it can cause reactivation. * **Drug of Choice for Fistulizing Crohn’s:** Infliximab. * **Integrin Antagonist:** Vedolizumab is a gut-selective agent used when TNF inhibitors fail.

Q: Which sulfa drug is used in inflammatory bowel disease?

Sulfasalazine. **Explanation** **Sulfasalazine** is the correct answer because it is a prodrug specifically designed to treat Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis and Crohn’s disease [1]. It consists of two components linked by a **diazo bond**: **5-Aminosalicylic acid (5-ASA)** and **Sulfapyridine** [1]. * **Mechanism:** The drug remains unabsorbed in the small intestine. Upon reaching the colon, bacterial enzymes (azoreductases) cleave the diazo bond [1]. * **Active Component:** 5-ASA (Mesalamine) acts locally to inhibit prostaglandin and leukotriene synthesis, providing the anti-inflammatory effect [2]. * **Carrier Component:** Sulfapyridine serves only as a carrier to deliver 5-ASA to the colon but is responsible for most of the drug's systemic side effects. **Analysis of Incorrect Options:** * **B. Sulfamethoxazole:** A systemic sulfonamide typically combined with Trimethoprim (Cotrimoxazole) to treat bacterial infections (e.g., UTI, PCP pneumonia). It has no specific role in IBD. * **C. Sulfinpyrazone:** A uricosuric agent used in the management of chronic gout. It inhibits the reabsorption of uric acid in the proximal tubule. * **D. Sulphadoxine:** A long-acting sulfonamide used primarily in combination with Pyrimethamine for the treatment of chloroquine-resistant malaria. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** Sulfasalazine commonly causes reversible **oligospermia** and hypersensitivity reactions (due to the sulfa moiety). * **Supplementation:** It inhibits folate absorption; hence, **folic acid supplementation** is mandatory. * **Alternatives:** **Olsalazine** (two 5-ASA molecules) and **Balsalazide** are used in patients intolerant to the sulfa component of sulfasalazine [1], [3].

Q: Which antiemetic is associated with the following adverse drug reaction?

Dronabinol. ***Dronabinol*** - **Conjunctival injection** (red/bloodshot eyes) is a classic adverse drug reaction of dronabinol, a **synthetic cannabinoid** antiemetic. - Other common side effects include **euphoria**, **dizziness**, and **dry mouth** due to its cannabinoid receptor activity. *Domperidone* - A **dopamine D2 receptor antagonist** that primarily causes **cardiac arrhythmias** and **QT prolongation** as major adverse effects. - Does not cause **conjunctival injection** as it works peripherally and doesn't cross the blood-brain barrier significantly. *Granisetron* - A **5-HT3 receptor antagonist** commonly associated with **headache** and **constipation** as primary adverse effects. - **Conjunctival injection** is not a recognized side effect of this serotonin receptor antagonist. *Aprepitant* - An **NK1 receptor antagonist** that typically causes **fatigue**, **hiccups**, and **decreased appetite** as main adverse reactions. - Does not cause **conjunctival injection** as its mechanism involves neurokinin-1 receptor blockade, not cannabinoid pathways.

Q: Which of the following drugs is not a component of triple drug therapy for Helicobacter pylori?

Cimetidine. The standard **Triple Drug Therapy** for *Helicobacter pylori* eradication consists of a Proton Pump Inhibitor (PPI) combined with two antibiotics [2]. The goal is to reduce gastric acidity (to allow mucosal healing and enhance antibiotic stability) and eliminate the bacteria. **Why Cimetidine is the correct answer:** Cimetidine is an **H₂-receptor antagonist** [1]. While it reduces acid secretion, it is **not** part of the standard triple therapy regimen [2]. Modern protocols favor PPIs over H₂ blockers because PPIs provide more potent and sustained acid suppression, which is crucial for the efficacy of antibiotics like Clarithromycin and Amoxicillin against *H. pylori* [2]. **Analysis of incorrect options:** * **Lansoprazole (Option A):** This is a PPI [1]. A PPI (e.g., Omeprazole, Lansoprazole, or Rabeprazole) is a mandatory component of triple therapy to maintain a gastric pH > 4 [2]. * **Clarithromycin (Option B):** A macrolide antibiotic that inhibits bacterial protein synthesis. It is the most effective antibiotic against *H. pylori* and is a core component of the regimen. * **Metronidazole (Option C):** An imidazole antibiotic used as an alternative to Amoxicillin, especially in patients with penicillin allergy or in regions with specific resistance patterns. **High-Yield Clinical Pearls for NEET-PG:** 1. **Standard Triple Therapy (7–14 days):** PPI + Clarithromycin (500mg) + Amoxicillin (1g) OR Metronidazole (400mg) twice daily. (Mnemonic: **CAP** – Clarithromycin, Amoxicillin, PPI). 2. **Sequential Therapy:** Involves 5 days of PPI + Amoxicillin, followed by 5 days of PPI + Clarithromycin + Tinidazole. 3. **Quadruple Therapy:** Used in cases of Clarithromycin resistance. It includes **Bismuth subsalicylate** + PPI + Tetracycline + Metronidazole. 4. **Drug of Choice:** PPIs are the DOC for both *H. pylori* eradication and NSAID-induced ulcers.

Question 1

Which of the following drugs is NOT indicated in drug-induced vomiting?

Accepted Answer

Hyoscine

Answer

Metoclopramide

Answer

Ondansetron

Answer

Chlorpromazine

Question 2

Which of the following is useful to decrease mortality and renal failure in acute liver disease due to alcoholism?

Accepted Answer

Pentoxifylline

Answer

Orlistat

Answer

S-Adenosyl methionine

Answer

Syrlamysin

Question 3

Which of the following drugs inhibits the release of acetylcholine from cholinergic nerves in the submucosa and myenteric complex?

Accepted Answer

Loperamide

Answer

Pectin

Answer

Docusate

Answer

Cholestyramine

Question 4

Which drug is implicated for prolonging the QT interval in a premature baby?

Accepted Answer

Cisapride

Answer

Domperidone

Answer

Metoclopramide

Answer

Omeprazole

Question 5

What makes the combination of magnesium and aluminum hydroxide superior as an antacid?

Accepted Answer

All of the above.

Answer

They possess rapid and sustained acid-neutralizing properties.

Answer

They have less effect on gastric emptying.

Answer

They are less likely to alter bowel movements.

Question 6

Which one of the drugs is useful in treating Crohn's disease?

Accepted Answer

Infliximab

Answer

Azathioprine

Answer

Tacrolimus

Answer

Cyclosporine

Question 7

Despite their short half-lives (2 hours), Proton Pump Inhibitors (PPIs) cause a prolonged suppression of acid secretion (up to 48 hours) because:

Accepted Answer

They irreversibly inhibit the proton pump molecule and hence, acid secretion requires synthesis of new proton pumps.

Answer

They are prodrugs and undergo activation gradually.

Answer

They exit from the plasma and enter acid secretory canaliculi and stay there, blocking the secretion of acid for a long time.

Answer

They are available as enteric coated capsules, from which drug is gradually released.

Question 8

Which sulfa drug is used in inflammatory bowel disease?

Accepted Answer

Sulfasalazine

Answer

Sulfamethoxazole

Answer

Sulfinpyrazone

Answer

Sulphadoxine

Question 9

Which antiemetic is associated with the following adverse drug reaction?

Accepted Answer

Dronabinol

Answer

Domperidone

Answer

Granisetron

Answer

Aprepitant

Question 10

Which of the following drugs is not a component of triple drug therapy for Helicobacter pylori?

Accepted Answer

Cimetidine

Answer

Lansoprazole

Answer

Clarithromycin

Answer

Metronidazole

Drugs for Gastrointestinal Diseases — MCQs

Drugs for Gastrointestinal Diseases — MCQs

On this page

Practice by Chapter

Want unlimited practice?